Polymeric Diet Alone Versus Corticosteroids in the Treatment of Active Pediatric Crohn’s Disease: A Randomized Controlled Open-Label Trial

Clinical Gastroenterology and Hepatology ◽

10.1016/j.cgh.2006.03.010 ◽

2006 ◽

Vol 4 (6) ◽

pp. 744-753 ◽

Author(s):

Osvaldo Borrelli ◽

Letizia Cordischi ◽

Manuela Cirulli ◽

Massimiliano Paganelli ◽

Valeria Labalestra ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Randomized Controlled ◽

Open Label Trial

Download Full-text

Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial

Gastroenterology ◽

10.1016/s0016-5085(99)70276-3 ◽

1999 ◽

Vol 117 (6) ◽

pp. 1271-1277 ◽

Author(s):

Eli D. Ehrenpreis ◽

Sunanda V. Kane ◽

Lawrence B. Cohen ◽

Russell D. Cohen ◽

Stephen B. Hanauer

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Open Label Trial

Download Full-text

Laparoscopic Ileocecal Resection versus Infliximab for Terminal Ileitis in Crohn’s Disease: a Randomized, Controlled, Open-Label, Multicentre Trial Lancet Gastroenterol Hepatol 2017;2:785–92

Côlon & Rectum ◽

10.3166/cer-2018-0012 ◽

2018 ◽

Vol 12 (2) ◽

pp. 111-113

Author(s):

Y. Panis

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Multicentre Trial ◽

Ileocecal Resection ◽

Terminal Ileitis ◽

Randomized Controlled ◽

Laparoscopic Ileocecal Resection

Download Full-text

A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease

Alimentary Pharmacology & Therapeutics ◽

10.1111/apt.12051 ◽

2012 ◽

Vol 36 (9) ◽

pp. 850-857 ◽

Author(s):

F. Zorzi ◽

E. Calabrese ◽

I. Monteleone ◽

M. Fantini ◽

S. Onali ◽

...

Keyword(s):

Crohn’S Disease ◽

Small Bowel ◽

Crohn's Disease ◽

Antisense Oligonucleotide ◽

Phase 1 ◽

Open Label Trial

Download Full-text

Open label trial of oral clarithromycin in active Crohn’s disease

Alimentary Pharmacology & Therapeutics ◽

10.1046/j.1365-2036.2000.00753.x ◽

2000 ◽

Vol 14 (6) ◽

pp. 801-806 ◽

Author(s):

Leiper ◽

Morris ◽

Rhodes

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Open Label Trial

Download Full-text

Clinical efficacy of treatment with infliximab in a german multicenter, prospective, open-label trial in refractory crohn's disease

Gastroenterology ◽

10.1016/s0016-5085(00)84408-x ◽

2000 ◽

Vol 118 (4) ◽

pp. A568 ◽

Author(s):

S. Schreiber ◽

T. Kuehbacher ◽

S. Mascheretti ◽

E. Hommel ◽

C. Pohl ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Clinical Efficacy ◽

Open Label Trial ◽

Efficacy Of Treatment

Download Full-text

Clinical and immunological effects of ornidazole in active Crohn's disease: An 8 - week open label trial

Gastroenterology ◽

10.1016/0016-5085(95)27546-0 ◽

1995 ◽

Vol 108 (4) ◽

pp. A809

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Immunological Effects ◽

Open Label Trial

Download Full-text

Faculty of 1000 evaluation for A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717958516.793470215 ◽

2013 ◽

Author(s):

Eduard Stange

Keyword(s):

Crohn’S Disease ◽

Small Bowel ◽

Crohn's Disease ◽

Antisense Oligonucleotide ◽

Phase 1 ◽

Open Label Trial

Download Full-text

Tu2018 - Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: Initial Results from a Phase I Open-Label Randomized Controlled Trial in Patients with Active Crohn's Disease

Gastroenterology ◽

10.1016/s0016-5085(18)34477-9 ◽

2018 ◽

Vol 154 (6) ◽

pp. S-1371 ◽

Author(s):

Stefan Schreiber ◽

Byung Ik Jang ◽

Vladimir Borzan ◽

Adi Lahat ◽

Aldis Pukitis ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Phase I ◽

Controlled Trial ◽

Subcutaneous Administration ◽

Randomized Controlled ◽

Initial Results

Download Full-text

Tu1715 – A Novel Formulation of Ct-P13 (Infliximab Biosimilar) for Subcutaneous Administration: 1-Year Result from a Phase I Open-Label Randomized Controlled Trial in Patients with Active Crohn's Disease

Gastroenterology ◽

10.1016/s0016-5085(19)39701-x ◽

2019 ◽

Vol 156 (6) ◽

pp. S-1096 ◽

Author(s):

Byong Duk Ye ◽

Byung Ik Jang ◽

Vladimir Borzan ◽

Adi Lahat ◽

Aldis Pukitis ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Phase I ◽

Controlled Trial ◽

Subcutaneous Administration ◽

Randomized Controlled

Download Full-text

Faculty Opinions recommendation of Crohn's disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735919047.793568128 ◽

2019 ◽

Author(s):

Ashish Patel

Keyword(s):

Randomized Controlled Trial ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Enteral Nutrition ◽

Controlled Trial ◽

Sustained Remission ◽

Randomized Controlled ◽

Download Full-text